Immune Targeting Systems | Date: 2014-05-23
The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.
Immune Targeting Systems | Date: 2013-06-10
Pharmaceutical preparations and substances; vaccines; pharmaceuticals for immunotherapies. Medical research and development; research and development of vaccines and immunotherapies; synthesising vaccines.
Immune Targeting Systems | Date: 2012-07-21
pharmaceutical preparations and substances for the treatment of flu; vaccines except for gynecological and vaginal purposes; immunotherapies products, namely, vaccine preparations against flu. medical research and development; medical research, development, engineering and testing services in the field of synthesizing vaccines.
Immune Targeting Systems | Date: 2013-02-05
Pharmaceutical preparations in the nature of immunotherapies for the treatment of viral and infectious diseases, and for the treatment of cancer; vaccines. Medical research; medical development, namely, synthesising vaccines and immunotherapies.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 2.03M | Year: 2013
In Europe there are an estimated 14 million citizens living with chronic hepatitis B virus (HBV) infection, nearly a quarter of those will die of liver failure or liver cancer as a direct result of the viral infection, accounting for >36,000 deaths per annum. As a consequence HBV is a significant burden to healthcare systems across Europe through the direct costs of treatment, as well as indirect costs linked to lost productivity and premature death. Immune Targeting Systems (ITS) is developing a novel fluoropeptide vaccine immunotherapy (Hepsyn-B), based on its proprietary Depovaccine and Densigen technologies, to induce immune control over the disease, increase likelihood of the clearance of infected liver cells and reducing the need for prolonged costly drug therapy. This project provides the opportunity to expedite the pre-clinical development of Hepsyn-B and demonstrate vaccine safety, efficacy and manufacturability in preparation for human clinical trials.